ERAS vs. BDTX, SBTX, NKTR, ATAI, NKTX, KMDA, MRSN, ADCT, VSTM, and AVIR
Should you be buying Erasca stock or one of its competitors? The main competitors of Erasca include Black Diamond Therapeutics (BDTX), Silverback Therapeutics (SBTX), Nektar Therapeutics (NKTR), Atai Life Sciences (ATAI), Nkarta (NKTX), Kamada (KMDA), Mersana Therapeutics (MRSN), ADC Therapeutics (ADCT), Verastem (VSTM), and Atea Pharmaceuticals (AVIR). These companies are all part of the "medical" sector.
Erasca (NASDAQ:ERAS) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, community ranking, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.
Black Diamond Therapeutics received 23 more outperform votes than Erasca when rated by MarketBeat users. Likewise, 63.93% of users gave Black Diamond Therapeutics an outperform vote while only 61.54% of users gave Erasca an outperform vote.
In the previous week, Black Diamond Therapeutics had 3 more articles in the media than Erasca. MarketBeat recorded 11 mentions for Black Diamond Therapeutics and 8 mentions for Erasca. Black Diamond Therapeutics' average media sentiment score of 1.09 beat Erasca's score of -0.28 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.
67.8% of Erasca shares are held by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are held by institutional investors. 29.8% of Erasca shares are held by insiders. Comparatively, 8.9% of Black Diamond Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Erasca currently has a consensus price target of $7.83, suggesting a potential upside of 302.74%. Black Diamond Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 142.91%. Given Erasca's higher possible upside, analysts clearly believe Erasca is more favorable than Black Diamond Therapeutics.
Erasca's return on equity of -38.83% beat Black Diamond Therapeutics' return on equity.
Erasca has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500. Comparatively, Black Diamond Therapeutics has a beta of 2.56, indicating that its share price is 156% more volatile than the S&P 500.
Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.
Summary
Black Diamond Therapeutics beats Erasca on 8 of the 14 factors compared between the two stocks.
Get Erasca News Delivered to You Automatically
Sign up to receive the latest news and ratings for ERAS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ERAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
